Affymetrix to Launch Next-Gen Cytogenetics Array in Q3, Plans FDA Submission
May 10, 2011
Affymetrix to Launch Next-Gen Cytogenetics Array in Q3, Plans FDA Submission
Affymetrix expects CytoScan HD to "set performance standards" in the cytogenetics research market, and believes that the new chip will have the "broadest degree of coverage for constitutional and cancer applications."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Affymetrix to Start Clinical Trials for CytoScan HD in March, Plans FDA Submission by Midyear
January 17, 2012 / BioArray News - Consumer Genetics Sales, GWAS, BlueGnome Drive Illumina Q1 Microarray Revenue Growth
April 23, 2013 / BioArray News - Affy Files CytoScan with FDA, Plans 'Aggressive' Marketing Campaign to Grow Cyto Business
February 19, 2013 / BioArray News - After 'Pivotal' 2012, Affy Looks to CytoScan, Axiom Genotyping Products to Drive Future Growth
February 5, 2013 / BioArray News - At JP Morgan, Affy Provides Update on Cyto FDA Submission, New Genotyping Products, Restructuring
January 15, 2013 / BioArray News